Intelligence Feed event · Equity · 2026-10-21

    HUTCHMED closed a KRAS-EGFR license with GSK outside China

    Question

    HUTCHMED closed a KRAS-EGFR license with GSK outside China

    Direct answer

    The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “HUTCHMED closed a KRAS-EGFR license with GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/hutchmed-closed-a-kras-egfr-license-with-gsk-outside-china-9b7948

    EQUITY
    HUTCHMED closed a KRAS-EGFR license with GSK outside China
    The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.
    HCMGSK
    Impact
    59
    YESTERDAY
    SIG
    89%
    HCMGSK
    HUTCHMED closed a KRAS-EGFR license with GSK outside China
    The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.
    → The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.
    Impact
    The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.
    Affected
    HCMGSK
    Transmission
    The license payment and global rights shift support HCM cash flow and add optionality to GSK's oncology pipeline valuation.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCM$110 million upfront payment via out-licensing proceedsUp1-5dHUTCHMED will receive $110 million upfront.
    GSKoncology pipeline optionality via ex-China rights acquisitionMixed1-5dGSK subsidiary receives worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month